Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Pharmacy Marketing Drugs 98

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Marketing Drugs Production 98

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Read on for Steve’s insights. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharma Companies Marketing Drugs 98

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Drugs Production Marketing 98

Drug Channels

SEPTEMBER 13, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements. d/b/a Drug Channels Institute.

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

Drug Channels

DECEMBER 12, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Hospitals Marketing 98

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my nearly 30,000 (!)

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

DECEMBER 11, 2023

One update: CVS Caremark's 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, Sandoz products are marketed by Cordavis, the new business described in today's rerun.

Biosimilars 75

Biosimilars Pharmacy Production Marketing 75

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 75

Biosimilars Pharmacy Drugs Marketing 75

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m. d/b/a Drug Channels Institute.

Marketing 97

Marketing Biosimilars Drugs Hospitals 97

Drug Channels

DECEMBER 17, 2020

Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. d/b/a Drug Channels Institute.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

MARCH 30, 2023

So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Drugs Production 75

Drug Channels

AUGUST 16, 2024

Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. The findings shed light on payers' view of biosimilar conpetition, contracting challenges, and other issues.

Biosimilars 78

Biosimilars Marketing Production Research 78

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. Read on for Saket’s insights.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

Drug Channels

SEPTEMBER 4, 2024

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. All rights reserved.

Biosimilars 52

Biosimilars Production Marketing Drugs 52

Drug Channels

APRIL 3, 2024

The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

Drug Channels

MARCH 5, 2024

WHAT YOU WILL LEARN In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. As always, Dr. Please note that Dr. Fein will focus on the IRA’s patient and commercial market impacts.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

OCTOBER 7, 2024

What are the market impacts of innovative models such as Mark Cuban's Cost Plus Drugs and Amazon's pharmacy model? What market dynamics and barriers are impacting pricing and demand? What can be learned from the economic landscape of biosimilars and specialty therapeutics? What's on the horizon for alternative PBMs?

Pharmacy 97

Pharmacy Biosimilars Compliance Marketing 97

Drug Channels

NOVEMBER 14, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.

Pharmacy 98

Pharmacy Drugs Biosimilars Marketing 98

Drug Channels

NOVEMBER 8, 2021

Year after year, the life science industry marks Informa Connect’s Trade and Channel Strategies as the “go-to” event for trade, channel, market access, account strategy and brand professionals. Copyright © 2006-2021 Pembroke Consulting, Inc. The full agenda for this year’s Trade and Channel Strategies conference is available now!

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Biosimilars Marketing 75

Drug Channels

OCTOBER 17, 2022

Join your colleagues from across the industry and be part of critical, solution-focused discussions designed to help optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement, all delivered by an expert speaking faculty. Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Therapies Production 75

Drug Channels

JULY 11, 2022

Director, Cell Therapy Operations and Patient Services, Gamida Cell Austin Fisher, Executive Director, CART Patient Support and Distribution, Autolus Chris Boneham, Vice President Market Access U.S., Copyright © 2006-2022 Pembroke Consulting, Inc. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

Drug Channels

OCTOBER 5, 2021

Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: Biosimilars Are Delivering Higher Profits for Drug Distributors (press release) We’re offering special discounted pricing if you order before October 15, 2021! Section 4.4.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

Drug Channels

NOVEMBER 15, 2021

Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. Read on for full details on pricing and registration. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 72

Specialty Pharmacies Biosimilars Drugs Pharmacy 72

Drug Channels

OCTOBER 11, 2022

Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom (press release) We’re offering special discounted pricing if you order before October 21, 2022! We also update sections that were introduced in recent editions, such as our estimates of wholesalers' profits from provider-administered biosimilar drugs.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Drug Channels

JUNE 26, 2023

Copyright © 2006-2023 Pembroke Consulting, Inc. View the agenda for Health Systems & Pharma Partnering 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/health-systems-partnering for further details and to register. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars Pharmacy Science Therapies 75

Drug Channels

MAY 29, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Click here to learn more and reserve your spot at the June 21 event. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

Drug Channels

OCTOBER 23, 2023

A program driven by market dynamics and led by champions of channel strategy, join now to master the complexities of pharmacy and distribution models to accelerate market access –It's all happening December 11-13, 2023. Why should you attend this pivotal event? How is health policy affecting the distribution channel?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

OCTOBER 15, 2023

Copyright © 2006-2023 Pembroke Consulting, Inc. View the agenda the 2023 PBM Contracting Summit to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/pbm-contracting for further details and to register. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc.,

Biosimilars 74

Biosimilars Drugs Marketing 74

Drug Channels

JUNE 24, 2020

My recent tweets have highlighted: Amazon’s activities, PillPack’s bad reviews, 340B outrages, rebate reform redux, biosimilar pricing, managed Medicaid market shares, drug pricing, blockchain hype, and the warp speed vs. hyperspace debate. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Biosimilars Drugs Marketing 52

Drug Channels

MARCH 14, 2023

Prescription Market (press release) We’re offering special discounted pricing if you order before April 3, 2023. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. The 2023 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. Please contact us if you did not receive the email.

Pharmacy 98

Pharmacy Drugs Marketing Biosimilars 98

Drug Channels

JULY 23, 2024

Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. As I noted last week, multiple forces are poised to pop the gross-to-net bubble for high-list/high-rebate products. All rights reserved.

Biosimilars 52

Biosimilars Pharmaceuticals Production Drugs 52

Drug Channels

JUNE 5, 2023

View the Agenda Snapshot Enhance Patient Service, Network Design, and Channel Strategies to Improve Patient Access and Support In its 8th year, the Specialty Network and Patient Support Services Summit is an important event for senior leaders in patient access, trade, channel, market access, brand and account strategy.

Specialty Pharmacies 74

Specialty Pharmacies Pharmacy Biosimilars Compliance 74

Drug Channels

FEBRUARY 21, 2023

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. Copyright © 2006-2023 Pembroke Consulting, Inc. Click to Enlarge] Thank you for your interest in our work.

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

The Pharma Data

APRIL 4, 2023

Biosimilars help patients to gain broader access to effective and high-quality treatments that improve their disease therapies,” said Rebecca Guntern, Head of Region Europe, Sandoz. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

Biosimilars 40

Biosimilars Pharmacokinetics FDA Approval Packaging 40